Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07705919 Albumin-Bound Paclitaxel Pancreatic Ductal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07705919 clinical trial report covering Albumin-Bound Paclitaxel, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07708194 Pyrotinib Maleate Hormone receptor positive breast cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07708194 clinical trial report covering Pyrotinib Maleate, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07706855 GKL-006RTU Respiratory Distress Syndrome, Acute Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07706855 clinical trial report covering GKL-006RTU, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07706959 Zeprumetostat Peripheral T-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07706959 clinical trial report covering Zeprumetostat, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07708285 Serplulimab Meningioma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07708285 clinical trial report covering Serplulimab, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07707895 Zocilurtatug Pelitecan Small cell lung cancer limited stage Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07707895 clinical trial report covering Zocilurtatug Pelitecan, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262727 BY-101921 Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
CTR20262727 clinical trial report covering BY-101921, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07711210 ACC-017 HIV Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07711210 clinical trial report covering ACC-017, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
CTR20262751 SGT003 (Sungen) Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
CTR20262751 clinical trial report covering SGT003 (Sungen), Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07712562 Dibotatug Anemia, Aplastic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07712562 clinical trial report covering Dibotatug, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07711223 Asuptegravir/Emtricitabine/Tenofovir Alafenamide HIV Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07711223 clinical trial report covering Asuptegravir/Emtricitabine/Tenofovir Alafenamide, Phase 1/2, endpoints, sponsor, geography, readout timing and d
Latest Hotspot
8 min read
NCT07714395 Elraglusib Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07714395 clinical trial report covering Elraglusib, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.